Tacrolimus in refractory polymyositis with interstitial lung disease

Anti-Jo-1 is the most frequently identified autoantibody in the idiopathic inflammatory myopathies. The effectiveness of tacrolimus in treating such patients is discussed.

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 1999-05, Vol.353 (9166), p.1762-1763
Main Authors: ODDIS, C. V, SCIURBA, F. C, ELMAGD, K. A, STARZL, T. E
Format: Article
Language:English
Subjects:
Adult
Aged
Autoantibodies - blood
Biological and medical sciences
Creatine Kinase - blood
Disease
Drug therapy
Female
Hand Strength
Health care
Humans
Immunomodulators
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Lung Diseases, Interstitial - drug therapy
Lung Diseases, Interstitial - etiology
Lungs
Medical research
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Polymyositis - complications
Polymyositis - drug therapy
Polymyositis - immunology
Tacrolimus - adverse effects
Tacrolimus - therapeutic use
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti-Jo-1 is the most frequently identified autoantibody in the idiopathic inflammatory myopathies. The effectiveness of tacrolimus in treating such patients is discussed.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(99)01927-3